Literature DB >> 25120093

Development of CMX001 (Brincidofovir) for the treatment of serious diseases or conditions caused by dsDNA viruses.

Diana F Florescu1, Megan A Keck.   

Abstract

CMX001 (hexadecyloxypropyl-cidofovir, Brincidofovir) is a broad spectrum, lipid conjugate of cidofovir that is converted intracellularly into the active antiviral, cidofovir diphosphate. The lipid conjugation results in oral bioavailability, higher intracellular concentrations of active drug, lower plasma concentrations of cidofovir and increased antiviral potency against dsDNA viruses.

Entities:  

Keywords:  BK virus; Brincidofovir; CMX001; JC virus; adenovirus; cytomegalovirus; dsDNA virus; molluscum; orthopoxvirus; vaccinia virus

Mesh：

Substances：

Year:  2014        PMID： 25120093     DOI： 10.1586/14787210.2014.948847

Source DB:  PubMed          Journal:  Expert Rev Anti Infect Ther        ISSN： 1478-7210            Impact factor:   5.091


  31 in total

1.  Ebola: Embed research in outbreak response.

Authors:  Trudie Lang
Journal:  Nature       Date:  2015-08-06       Impact factor: 49.962

2.  The cumulative burden of double-stranded DNA virus detection after allogeneic HCT is associated with increased mortality.

Authors:  Joshua A Hill; Bryan T Mayer; Hu Xie; Wendy M Leisenring; Meei-Li Huang; Terry Stevens-Ayers; Filippo Milano; Colleen Delaney; Mohamed L Sorror; Brenda M Sandmaier; Garrett Nichols; Danielle M Zerr; Keith R Jerome; Joshua T Schiffer; Michael Boeckh
Journal:  Blood       Date:  2017-02-16       Impact factor: 22.113

Review 3.  Phosphonate prodrugs: an overview and recent advances.

Authors:  Kenneth M Heidel; Cynthia S Dowd
Journal:  Future Med Chem       Date:  2019-07       Impact factor: 3.808

4.  Human herpesvirus 6 in transplant recipients: an update on diagnostic and treatment strategies.

Authors:  Joshua A Hill
Journal:  Curr Opin Infect Dis       Date:  2019-12       Impact factor: 4.915

5.  USC-087 protects Syrian hamsters against lethal challenge with human species C adenoviruses.

Authors:  Karoly Toth; Jacqueline F Spencer; Baoling Ying; Ann E Tollefson; Caroll B Hartline; Eric T Richard; Jiajun Fan; Jinglei Lyu; Boris A Kashemirov; Cheryl Harteg; Dawn Reyna; Elke Lipka; Mark N Prichard; Charles E McKenna; William S M Wold
Journal:  Antiviral Res       Date:  2018-03-03       Impact factor: 5.970

6.  Efficacy of brincidofovir as prophylaxis against HSV and VZV in hematopoietic cell transplant recipients.

Authors:  Yeon Joo Lee; Dionysios Neofytos; Seong Jin Kim; Leslie Cheteyan; Yao-Ting Huang; Esperanza B Papadopoulos; Ann A Jakubowski; Genovefa A Papanicolaou
Journal:  Transpl Infect Dis       Date:  2018-09-03       Impact factor: 2.228

7.  Updates on Treatment of Ebola Virus Disease.

Authors:  Lakshmi Krishnasamy; Chitralekha Saikumar
Journal:  Malays J Med Sci       Date:  2015-11

8.  New drug on the horizon for treating adenovirus.

Authors:  William S M Wold; Karoly Toth
Journal:  Expert Opin Pharmacother       Date:  2015-09-02       Impact factor: 3.889

9.  Comparison of three dimensional synergistic analyses of percentage versus logarithmic data in antiviral studies.

Authors:  Donald F Smee; Mark N Prichard
Journal:  Antiviral Res       Date:  2017-07-01       Impact factor: 5.970

10.  Kinetics of Double-Stranded DNA Viremia After Allogeneic Hematopoietic Cell Transplantation.

Authors:  Joshua A Hill; Bryan T Mayer; Hu Xie; Wendy M Leisenring; Meei-Li Huang; Terry Stevens-Ayers; Filippo Milano; Colleen Delaney; Keith R Jerome; Danielle M Zerr; Garrett Nichols; Michael Boeckh; Joshua T Schiffer
Journal:  Clin Infect Dis       Date:  2018-01-18       Impact factor: 9.079
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.